BioCardia reported Q3 2024 financial results with reduced losses as research costs declined following the completion of CardiAMP Heart Failure Trial enrollment. Net loss decreased to $1.7M from $2.6M YoY, while R&D expenses dropped to $931,000 from $1.9M. The company raised $7.2M through a public offering in September 2024.The CardiAMP Heart Failure Trial has completed its last protocol-specified follow-up visit, with data lock expected in Q4 2024 and top-line results anticipated in Q1 2025. The FDA has accepted plans for trial completion and approved protocol amendments for the confirmatory CardiAMP Heart Failure II Trial. Additionally, BioCardia has engaged with Japan's PMDA regarding potential approval based on U.S. data.The company achieved several milestones, including FDA 510(k) approval for its Morph DNA Steerable Introducer product family and progress in other clinical programs. The last patient in the CardiAMP chronic myocardial ischemia trial's open-label cohort was treated in August 2024, with primary endpoint data expected in Q1 2025.

BioCardia reported Q3 2024 financial results with reduced losses as research costs declined following the completion of CardiAMP Heart Failure Trial enrollment. Net loss decreased to $1.7M from $2.6M YoY, while R&D expenses dropped to $931,000 from $1.9M. The company raised $7.2M through a public offering in September 2024.The CardiAMP Heart Failure Trial has completed its last protocol-specified follow-up visit, with data lock expected in Q4 2024 and top-line results anticipated in Q1 2025. The FDA has accepted plans for trial completion and approved protocol amendments for the confirmatory CardiAMP Heart Failure II Trial. Additionally, BioCardia has engaged with Japan's PMDA regarding potential approval based on U.S. data.The company achieved several milestones, including FDA 510(k) approval for its Morph DNA Steerable Introducer product family and progress in other clinical programs. The last patient in the CardiAMP chronic myocardial ischemia trial's open-label cohort was treated in August 2024, with primary endpoint data expected in Q1 2025.